COMMUNIQUÉS West-GlobeNewswire

PMV Pharma Announces Pricing of Oversubscribed $50 Million Public Offering of Securities
01/09/2026
PRINCETON, N.J., Aug. 31, 2026 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (“PMV Pharma” or the “Company”; Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule [...]
argenx to Present at Upcoming Investor Conferences
01/09/2026
September 1, 2026 Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology innovation company, today announced that members of the management team will participate in the following investor [...]
Novartis remibrutinib, a high-efficacy oral BTK inhibitor, significantly reduces relapse rates and shows favorable safety profile in Phase III RMS trials
01/09/2026
Ad hoc announcement pursuant to Art. 53 LR REMODEL-1/-2 trials met their primary endpoint, significantly reducing annualized relapse rate (ARR) vs teriflunomide in people living with relapsing multiple sclerosis (RMS) 1 [...]
Bavarian Nordic Launches First Tranche of New Share Buy-Back Program
01/09/2026
COPENHAGEN, Denmark, September 1, 2026 – Bavarian Nordic A/S (OMX: BAVA) today launches the first tranche of the new share buy-back program announced on August 21, under which the Company intends to repurchase own [...]
NexLife Expands Flat-Rate Compounded GLP-1 Program With Microdose and Sublingual Protocols
01/09/2026
Physician-led telehealth platform keeps compounded semaglutide and tirzepatide at one price from first dose through maintenance, with independent batch testing, one-to-two-day expedited delivery and $377 in nutrition, [...]
Health-ISAC® Invests in APAC with Key Staff Addition in Australia
01/09/2026
Simon Cowley joins Health-ISAC to strengthen the organization’s global presence and engagement across Australia, New Zealand, and the Asia-Pacific region MELBOURNE, Australia, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Health [...]
Disc Medicine Announces Multiple Presentations Across Portfolio at the Society of Hematologic Oncology (SOHO) 2026 Annual Meeting
01/09/2026
WATERTOWN, Mass., Aug. 31, 2026 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for [...]
YD Bio Limited Reports Unaudited Financial Results for the Six Months Ended June 30, 2026
01/09/2026
TAIPEI, Taiwan, Aug. 31, 2026 (GLOBE NEWSWIRE) -- YD Bio Limited (“YD Bio” or the “Company”) (Nasdaq: YDES), a biotechnology company advancing DNA methylation–based cancer detection technology and ophthalmologic [...]
Telix Appoints David Gill as Chair
01/09/2026
David Gill appointed Chair of the Telix Board, effective immediately. Mr. Gill joined Telix as a Non-Executive Director in May 2026, with the intention that he would become Chair. Dr. Mark Nelson will continue to serve [...]
Rakovina Therapeutics Announces Q2 2026 Financial Results and Provides Corporate Update
01/09/2026
All dollar amounts reflected in Canadian dollars unless otherwise stated. VANCOUVER, British Columbia, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO0), a biopharmaceutical company [...]
Rutland Regional Medical Center Earns Four U.S. News & World Report High Performing Ratings
01/09/2026
Vermont hospital recognized for diabetes, hip replacement, knee replacement and hip fracture care in U.S. News’ 2026-2027 Best Hospitals procedure and condition ratings Rutland, VERMONT, Aug. 31, 2026 (GLOBE NEWSWIRE [...]
Canada’s Drug Agency Issues Final Positive Recommendation Supporting Public Reimbursement of LEQEMBI® (lecanemab) for Early Alzheimer’s Disease
01/09/2026
An Important Step Forward for Access to LEQEMBI® for Eligible Patients in Canada TOKYO and CAMBRIDGE, Mass., Aug. 31, 2026 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. and Biogen Inc. (Nasdaq: BIIB), announced today that Canada’ [...]
Anteris to Present at September Healthcare Investor Conferences
31/08/2026
MINNEAPOLIS and BRISBANE, Australia, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (“Anteris” or the “Company”) (NASDAQ: AVR, ASX: AVR) a global healthcare company committed to designing, [...]
L’été se termine, mais les situations d’urgence se poursuivent : la Croix-Rouge canadienne rappelle l’importance de se préparer
31/08/2026
Même si l’été tire à sa fin, les risques demeurent. Il est essentiel de se tenir informé et de rester vigilant. OTTAWA, Ontario, 31 août 2026 (GLOBE NEWSWIRE) -- La fréquence des catastrophes augmente au Canada. Il [...]
Summer is ending, emergencies aren’t: The Canadian Red Cross urges Canadians to prepare
31/08/2026
While summer may be winding down, the need to stay informed, vigilant, and prepared remains critical OTTAWA, Ontario, Aug. 31, 2026 (GLOBE NEWSWIRE) -- As disasters become more frequent across Canada, knowing how to [...]
BridgeBio Announces Agreement with U.S. Government to Improve Affordability and Access to Critical Medicines for Americans
31/08/2026
- This voluntary agreement expands access for Medicaid patients to BridgeBio’s currently marketed medicine and lowers drug costs for Americans without jeopardizing innovation and sustainability in rare diseases - [...]
ArsenalBio Announces New Focus on In Vivo CAR T Programs to Leverage Investment in T cell Engineering
31/08/2026
Company to leverage its enabling technologies to expand into autoimmunity Strategic shift will align resources with the next phase of innovation in cell therapy Data from its clinical autologous cell therapy programs [...]
Kestra Medical Technologies to Report First Quarter Fiscal 2027 Financial Results on September 14
31/08/2026
KIRKLAND, Wash., Aug. 31, 2026 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd. (Nasdaq: KMTS), a leading wearable medical device and digital healthcare company, is scheduled to report first quarter fiscal 2027 [...]
PMV Pharmaceuticals Announces Updated Promising Rezatapopt Monotherapy Interim Ovarian Cancer Data From PYNNACLE Phase 2 Pivotal Trial
31/08/2026
46% ORR observed among 76 evaluable patients in the ovarian cancer cohort with a median duration of response of 10.0 months Recent FDA interaction supports NDA submission strategy for accelerated approval of rezatapopt [...]

Pages